旺山旺水

Shanghai Wangshan Wangshui Pharmaceutical is a China-based biotechnology company specializing in the research and development of innovative small molecule therapeutics. The company is best known for its development of VV116 (Mindevir), an oral nucleoside analog antiviral for COVID-19, which was developed in collaboration with the Shanghai Institute of Materia Medica and Junshi Biosciences. Wangshan Wangshui's pipeline extends beyond infectious diseases to include candidates for central nervous system conditions and metabolic disorders. The firm operates with a strong emphasis on translational medicine and maintains strategic partnerships with leading academic and research institutions in China.